GlySens

GlySens Incorporated is a privately held corporation devoted to developing the world’s first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes. The GlySens fully implanted sensor—demonstrated up to 18 month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance.

For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGMTM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. The GlySens ICGM system is currently undergoing clinical evaluation; initial human implant trials have been completed, and preparations for additional human trials are underway.

GlySens headquartered in United States, North America, operates in the Health Care, Manufacturing, Medical Device sector. The company focuses on Health Care and has secured $1.6B in funding across 48 round(s). With a team of 51-100 employees, GlySens is actively contributing to advancements in Health Care. Their latest funding round, Seed Round - GlySens, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.